What is the 13F Pro Quality Score for TGTX?

13F Pro ranks TG THERAPEUTICS, INC. (TGTX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TGTX's current score at https://13fpro.ai/research/TGTX (free sign-up required for the full ranking).

Which hedge funds own the most TGTX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of TGTX include BlackRock,, STATE STREET, VANGUARD PORTFOLIO MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/TGTX as soon as new 13F filings post.

Where does 13F Pro source TGTX data?

All TG THERAPEUTICS, INC. fundamentals and ownership data come directly from SEC EDGAR. TG THERAPEUTICS, INC. files with the SEC under CIK 1001316. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TGTX in?

TG THERAPEUTICS, INC. (TGTX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What are TGTX's largest expenses?

TG THERAPEUTICS, INC.'s latest 10-Q reports these as the largest expense items: Cost of revenue ($33.5M, +115% YoY); Selling, general and administrative expenses (other) ($73.1M, +89% YoY); Research and development expenses (other) ($43.5M, +1% YoY). Sourced directly from SEC EDGAR filing text for Q1 2026 (quarter ended March 31, 2026).

How often is TGTX research updated on 13F Pro?

TGTX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

TG THERAPEUTICS, INC.(TGTX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1001316 TGTX stock profile & AI dashboard →

13F Pro Quality Score

68.4/100

Rank #417 of 2,879 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

93.3/100

Profitability

96.0/100

Balance Sheet

99.4/100

Earnings Quality

30.0/100

Free Cash Flow

19.0/100

Institutional Flow

86.9/100

Revenue Scale

40.6/100

Dilution Risk

16.4/100

TGTX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for TG THERAPEUTICS, INC. (TGTX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TGTX at 68.4/100 on a 32-signal composite quality model, placing it at rank #417 of 2,879 stocks — the top 25% of the AI-ranked universe. TGTX scores in the top quartile across balance sheet strength (99.4), profitability (96.0), revenue growth (93.3). Areas of concern include free cash flow (19.0) and earnings quality (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 16.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), TG THERAPEUTICS, INC. reports quarterly revenue of $204.9M, net income of $19.8M, an operating margin of 17.0%. Top institutional holders of TGTX by reported 13-F value include BlackRock,, STATE STREET, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. TGTX trades on the Nasdaq exchange and files with the SEC under CIK 1001316. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TGTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for TG THERAPEUTICS, INC. directly from SEC EDGAR. TG THERAPEUTICS, INC.'s 13F Pro composite quality score has ranged between 8 and 92 since 2021, currently 68.4 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about TG THERAPEUTICS, INC.

Quirks, history, and lore behind TGTX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · focused on treatments for B-cell diseases and blood cancers.
2
The Numbers
A small-cap biotech with minimal product revenue for most of its life — the classic story of a company that burns cash while waiting for its FDA approvals to print money.
3
The History
Founded in the early 2000s, the company spent years developing a pipeline targeting hematologic malignancies and autoimmune disorders before landing its first commercial product.
4
The Secret
Its approved drug Ukoniq hit the market but was later voluntarily withdrawn — a brutal reminder that the FDA giveth and the safety data taketh away.
5
The Lore
The company regrouped and scored a major win with ublituximab, an anti-CD20 monoclonal antibody approved for relapsing forms of multiple sclerosis — a pivot that surprised many skeptics.
6
The Giveaway
Its MS therapy Briumvi launched to commercial fanfare, and its ticker — two letters that are basically just its own initials doubled — is one of the most on-the-nose symbols on Wall Street.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving TGTX's Business? Latest 10-Q Breakdown

✓ 22/22 datapoints verified

AI-extracted from TG THERAPEUTICS, INC.'s 10-Q filed 2026-05-06 — Q1 2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Product revenue surged 68% YoY to $201.3M driven by BRIUMVI US market penetration and Neuraxpharm supply sales, achieving net income of $19.8M.

Biggest Revenue Drivers

Total revenue: $204.9M+69% YoY

Product revenue, net$201.3M+68% YoY

BRIUMVI US sales of $194.8M plus $6.5M sales to Neuraxpharm; greater market penetration in US and commercial supply to ex-US partner.

License, milestone, royalty and other revenue$3.6M+201% YoY

$2.7M royalty revenue under Neuraxpharm Commercialization Agreement plus $0.9M for development and regulatory activities.

Largest Expense Items

Cost of revenue$33.5M+115% YoY

Primarily royalties owed to licensing partner, third-party manufacturing, distribution and overhead; prior-period benefited from pre-approval manufacturing expensed to R&D.

Selling, general and administrative expenses (other)$73.1M+89% YoY

Marketing and media spend and personnel-related costs associated with BRIUMVI commercialization.

Research and development expenses (other)$43.5M+1% YoY

License and milestone expenses for Precision License Agreement, increased clinical trial expenses, partially offset by lower manufacturing and development costs for subcutaneous ublituximab.

Margins: Gross margin improved significantly as pre-approval manufacturing costs were fully depleted and commercial-stage operations scaled. Operating income grew to $34.8M from $8.6M YoY despite SG&A expansion, demonstrating operating leverage as revenues accelerated.

Watch Items from the Filing

Customer concentration: Top 3 customers represent 89% of product revenue (42%, 27%, 20%); heavy reliance on specialty distributors for BRIUMVI commercialization.
Neuraxpharm performance critical: Ex-US partnership generates revenue from supply ($6.5M Q1) and milestone/royalties ($2.7M); partner execution determines ex-US upside potential.
Debt refinancing: Raised $750M term loan replacing $250M facility in March 2026, increasing indebtedness and extending maturity to 2031; board approved $300M share repurchase program.
Accumulated deficit of $1.1B remains despite Q1 profitability; company achieved net income but sustained long-term losses historically; continued commercialization execution critical.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q1 2026

$204.9M

Net Income

Q1 2026

$19.8M

Free Cash Flow

Q1 2026

$-17.9M

Operating Margin

Q1 2026

17.0%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+87.3% YoY

$616.3MFY 2025

FY21 $6.7MFY22 $2.8MFY24 $329.0MFY25 $616.3M

Net Income

+1812.4% YoY

$447.2MFY 2025

FY21 $-348.1MFY22 $-223.8MFY24 $23.4MFY25 $447.2M

Operating Income

+194.1% YoY

$123.3MFY 2025

FY21 $-344.8MFY22 $-218.3MFY24 $41.9MFY25 $123.3M

EPS (Diluted)

+1746.7% YoY

$2.77FY 2025

FY21 $-2.63FY22 $-1.65FY24 $0.15FY25 $2.77

Total Assets

+84.1% YoY

$1.06BFY 2025

FY21 $379.6MFY22 $193.6MFY24 $577.7MFY25 $1.06B

Total Debt

+0.5% YoY

$245.6MFY 2025

FY21 $68.7MFY22 $71.1MFY24 $244.4MFY25 $245.6M

Op. Cash Flow

+38.9% YoY

$-24.8MFY 2025

FY21 $-295.6MFY22 $-176.2MFY24 $-40.5MFY25 $-24.8M

Metric	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020	FY 2018
Revenue	$616.3M +87.3%	$329.0M +11713.4%	$2.8M -58.4%	$6.7M +4300.7%	$152.0K +0.0%	$152.0K
Net Income	$447.2M +1812.4%	$23.4M +110.4%	$-223.8M +35.7%	$-348.1M	—	—
Operating Income	$123.3M +194.1%	$41.9M +119.2%	$-218.3M +36.7%	$-344.8M -26.0%	$-273.6M -56.9%	$-174.4M
EPS (Diluted)	$2.77 +1746.7%	$0.15 +109.1%	$-1.65 +37.3%	$-2.63 -8.7%	$-2.42	—
Total Assets	$1.06B +84.1%	$577.7M +198.4%	$193.6M -49.0%	$379.6M -39.3%	$625.6M +648.2%	$83.6M
Total Debt	$245.6M +0.5%	$244.4M +243.6%	$71.1M +3.5%	$68.7M +32.0%	$52.1M	$0.00
Operating Cash Flow	$-24.8M +38.9%	$-40.5M +77.0%	$-176.2M +40.4%	$-295.6M -37.8%	$-214.5M -66.4%	$-128.9M

AI Insight: TGTX Financial Trends

Revenue nearly tripled from $73M to $205M in seven quarters, but Q1 2026 debt spike to $745M and equity contraction to $583M demand close scrutiny.

• Revenue grew consistently from $73M in Q2 2024 to $205M in Q1 2026, a 181% increase over seven quarters.

• Operating income rose from $9M in Q2 2024 to $50M in Q4 2025, though Q1 2026 pulled back to $35M.

• Operating cash flow has been erratic — negative in four of eight quarters — with Q1 2026 at -$18M despite strong revenue.

• Equity surged to $648M in Q4 2025 (aided by $391M net income in Q3 2025) but contracted to $583M in Q1 2026.

⚠ Total debt jumped from $246M in Q4 2025 to $745M in Q1 2026 — a $499M single-quarter increase requiring explanation.

⚠ Q3 2025 net income of $391M vs. operating income of $29M suggests a large non-operating gain — sustainability is unclear.

⚠ Operating cash flow conversion remains weak; confirm whether rising revenue will translate to sustained positive OCF.

AI Insight: TGTX Ratio Trends

Debt-to-equity collapsed from 1.27 to 0.38 across H2 2025 before rebounding to 1.28 in Q1 2026, while operating margins remain profitable but volatile quarter-to-quarter.

• Operating margin swung from 7.1% in Q1 2025 to 26.2% in Q4 2025, highlighting significant seasonal or deal-driven earnings variability.

• D/E ratio improved sharply from 1.27 in Q3 2024 to 0.38 by Q4 2025, signaling meaningful deleveraging over that stretch.

• TTM net profit margin of 66.0% far exceeds any single-quarter NPM, suggesting a large one-time gain distorts the trailing figure.

⚠ D/E spiked back to 1.28 in Q1 2026 after reaching 0.38 in Q4 2025 — reverses the prior deleveraging trend abruptly.

⚠ ROIC dropped from 22.6% in Q4 2025 to 10.5% in Q1 2026 — sharpest single-quarter ROIC decline in the dataset.

⚠ Q3 2025 NPM, ROE, and ROA are missing; opacity around that quarter's profitability warrants clarification.

Get alerted when TGTX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for TG THERAPEUTICS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TGTX

BlackRock, Inc.
$739.2M22,252,930 sh
STATE STREET CORP
$287.3M8,649,766 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$274.9M8,273,979 sh
VANGUARD CAPITAL MANAGEMENT LLC
$219.4M6,603,258 sh
Soleus Capital Management, L.P.
$133.9M4,029,319 sh
GEODE CAPITAL MANAGEMENT, LLC
$116.3M3,499,916 sh
Clearbridge Investments, LLC
$106.7M3,210,930 sh
GOLDMAN SACHS GROUP INC
$76.0M2,287,688 sh
CONGRESS ASSET MANAGEMENT CO /MA
$72.0M2,168,081 sh
JANE STREET GROUP, LLC
$67.8M2,041,669 sh

Fund	Value	Shares
BlackRock, Inc.	$739.2M	22,252,930
STATE STREET CORP	$287.3M	8,649,766
VANGUARD PORTFOLIO MANAGEMENT LLC	$274.9M	8,273,979
VANGUARD CAPITAL MANAGEMENT LLC	$219.4M	6,603,258
Soleus Capital Management, L.P.	$133.9M	4,029,319
GEODE CAPITAL MANAGEMENT, LLC	$116.3M	3,499,916
Clearbridge Investments, LLC	$106.7M	3,210,930
GOLDMAN SACHS GROUP INC	$76.0M	2,287,688
CONGRESS ASSET MANAGEMENT CO /MA	$72.0M	2,168,081
JANE STREET GROUP, LLC	$67.8M	2,041,669

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TGTX on your watchlist

Track score changes the day TG THERAPEUTICS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TGTX a good stock to buy?

13F Pro's AI-powered analysis of TG THERAPEUTICS, INC. (TGTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TGTX are available on the TGTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own TGTX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TGTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of TG THERAPEUTICS, INC.'s investment landscape.